NCT03610958已完成不适用
Prospective, Single Center, Open-labeled Single Arm Study, to Asses the Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss in Healthy Over Weight and Obese Subjects
Epitomee medical2 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2014年9月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 2
- 主要终点
- the change in subjects' weight presented as percent total body loss (%TBL)
研究概览
简要总结
Study design to demonstrate the safety and performance of the Epitomee Device
详细描述
Prospective, single center, open-labeled single arm study. The subjects will be enrolled in one investigational site. Subjects meeting eligibility criteria will receive multiple capsule intakes, 1 capsule twice daily for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •21 ≤ Age <65 years
- •28 < BMI ≤ 40 kg/m2
- •Healthy subject
- •Normal blood count and chemistry
- •Subject is able and willing to give informed consent
- •Subject is able and willing to participate in the study and follow protocol procedures
排除标准
- •A. General health and medication
- •Any history or evidence of significant cardiac, renal, neurologic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease or symptom which in the judgment of the investigator would interfere with the study or confound the results
- •Symptomatic or unbalanced metabolic syndrome, or, symptomatic or unbalanced type 2 diabetes - such patients with minor symptoms may be allowed according to the PI discretion
- •Intake of chronic medication which may affect the GI or interrupt with the treatment, unless approved by the PI discretion
- •Taking thyroid hormone deficiency drugs (such as L-thyroxine)
- •Hemoglobin level under 11 gm/dl
- •B. Weight loss history and status
- •Currently using pharmaceutical agents or food supplements for weight loss
- •History of weight reduction of more than 5% of total body weight in the past 6 months
- •Eating disorder such as anorexia, bulimia compulsory overeating or emotional eating*
- •C. Specific GI history and status
- •History or evidence of any active liver disease. (abnormal liver functions: >1.5 times upper limit)
- •Subject with Inflammatory Bowel Disease (IBD)
- •Significant swallowing disorders
- •Less than 3 natural bowel movements per week
- •Past history of any gastrointestinal surgery (excluding uncomplicated appendectomy)
- •Malabsorption disorders
- •History of food allergy according to PI decision
- •Female subjects who are breastfeeding or have a positive pregnancy test at screening or at any time during the study
- •History of alcohol or drug abuse within 6 months of screening
- •Mental disorders
- •Currently participating in an ongoing clinical study
结局指标
主要结局
the change in subjects' weight presented as percent total body loss (%TBL)
时间窗: Baseline, 12 weeks
Subjects loss of weight described as %TBL
Safety evaluation of the Device administration.
时间窗: Baseline, 12 weeks
Normal Gastroscopic examination as assessed by an independent safety committee.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
A Single Arm, Open-label First In Human Study for Assessing the Safety and Performance of the EpiFinder in Subjects With Clinical Indication for Lumbar Epidural Steroids Injection (ESI)Chronic PainNCT04047927Omeq Medical15
已完成
不适用
Treatment of Actinic Keratosis With 5% KOH SolutionActinic KeratosesNCT04024579Infectopharm Arzneimittel GmbH73
Unknown
4 期
Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer PatientsAdvanced Pancreatic CancerNCT04217096Fudan University40
已完成
不适用
Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective CraniotomyCerebrospinal Fluid LeakageNCT01295619Kuros Biosurgery AG41
进行中（未招募）
不适用
SIRONA 2 Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04012944Endotronix, Inc.81